Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-05-05

Clinical Trial Update: Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial assessing plasma exchange with Albutein 5% for efficacy and safety in amyotrophic lateral sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Albutein 5%

Snippet

Sponsor: Grifols Therapeutics LLC | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2021-05-05